Pfizer Shells Out $43 Billion for Cancer Drugmaker With Sales of Only $2.2 Billion
Pfizer CEO Albert Bourla explained the high-price purchase to reporters in March. “We are not buying the golden eggs,” he said. “We are acquiring the goose that is laying the golden eggs.”
https://childrenshealthdefense.org/defender/pfizer-seagen-cancer-drugs-monoclonal-antibodies/
Pfizer CEO Albert Bourla explained the high-price purchase to reporters in March. “We are not buying the golden eggs,” he said. “We are acquiring the goose that is laying the golden eggs.”
https://childrenshealthdefense.org/defender/pfizer-seagen-cancer-drugs-monoclonal-antibodies/
Pfizer Shells Out $43 Billion for Cancer Drugmaker With Sales of Only $2.2 Billion
Amid plummeting sales of its COVID-19 vaccines, Pfizer acquired Seagen, a biotech company that makes drugs designed to use monoclonal antibodies to deliver anti-cancer agents to tumors while limiting damage…
Children's Health DefenseLink FeedWrite a comment...
Sort by